

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S):	Draper <i>et al.</i>	CONFIRMATION NO.:	9127
APPLICATION NO.:	10/692,563	EXAMINER:	Sabiha Naim Qazi
FILING DATE:	October 24, 2003	ART UNIT:	1612
FOR:	SUBSTITUTED TETRACYCLINE COMPOUNDS FOR THE TREATMENT OF MALARIA		

Via EFS
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached modified Form PTO-1449, as well as copies of the listed documents.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action based on the merits in the above-identified case. Accordingly, no fee or certification is believed required. By waiver of 37 C.F.R. §1.98(a)(2)(ii), copies of any U.S. Patents or U.S. Published Applications are not submitted.

This Information Disclosure Statement is accompanied by the statement that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in 37 CFR 1.56(c) more than thirty days prior to the filing of this statement. This Information Disclosure Statement contains art cited by the European Patent Office in EP Application No. 10150482.7.


It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and sign the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By submitting this Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicants, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested.

Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No.: 16534-526002US.

Respectfully submitted,



Heidi A. Erlacher, Reg. No. 45,409
Christopher E. Olson, Reg. No. 55,510
Attorneys for Applicants
MINTZ LEVIN
Tel: 617-542-6000
Fax: 617-542-2241
Customer No. 30623

Date: May 28, 2010